Continued statin prescriptions after adverse reactions and patient outcomes: A cohort study

Annals of Internal Medicine

Volumn 167, Issue 4, 2017, Pages 221-227

  Zhang, Huabing ^a,c   Plutzky, Jorge ^a,c   Shubina, Maria ^b   Turchin, Alexander ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Harvard New Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COHORT ANALYSIS; COLD SWEAT; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY ANALYSIS; SIDE EFFECT; VERY ELDERLY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; STROKE; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATIENT OUTCOME ASSESSMENT; RETROSPECTIVE STUDIES; STROKE; WITHHOLDING TREATMENT;

EID: 85027453950     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0838     Document Type: Article

References (35)

1. Kearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25. [PMID: 18191683] doi:10.1016/S0140-6736(08)60104-X
2. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. [PMID: 21067804] doi:10.1016/S0140-6736(10)61350-5
3. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. [PMID: 22607822] doi:10.1016/S0140-6736(12)60367-5
4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-45. [PMID: 24222016] doi:10.1161/01.cir.0000437738.63853.7a
5. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013; 158:526-34. [PMID: 23546564] doi:10.7326/0003-4819-158-7-201304020-00004
6. Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr Pharm Des. 2014;20:6314-24. [PMID: 24953391]
7. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy. 2001;21:576-82. [PMID: 11349746]
8. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-9. [PMID: 18371492] doi:10.1016/j.ahj.2007.12.011
9. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80. [PMID: 22884278] doi:10.1016/j.cjca.2012.05.007
10. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-61. [PMID: 12132975]
11. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17:3669-89. [PMID: 22074437]
12. Degli Esposti L, Saragoni S, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012;34: 190-9. [PMID: 22284998] doi:10.1016/j.clinthera.2011.12.011
13. Haukka J, Niskanen L, Partonen T, Lönnqvist J, Tiihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf. 2012;21:61-9. [PMID: 21956915] doi:10.1002/pds.2255
14. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472-83. [PMID: 24079289] doi: 10.1016/j.jacl.2013.03.001
15. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005; 19:403-14. [PMID: 16453090]
16. Morrison FJ, Zhang H, Skentzos S, et al. Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease. Cardiorenal Med. 2014;4:225-33. [PMID: 25737687] doi:10.1159/000368914
17. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597-603. [PMID: 24016512] doi:10.1016/j.ahj.2013.06.004
18. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580-90. [PMID: 27039291] doi:10.1001/jama.2016.3608
19. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553-68. [PMID: 24267801] doi:10.1016/j.cjca.2013.09.023
20. Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA Annu Symp Proc. 2011;2011:1270-9. [PMID: 22195188]
21. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301-10. [PMID: 24737272] doi:10.7326/M13-1921
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70. [PMID: 10075613]
23. Lin DY, Wei L-J, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557-72.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
25. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73:751-4.
26. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-2.
27. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007;45: S103-7. [PMID: 17909367]
28. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24:3089-110. [PMID: 16189810]
29. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82:387-94.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70: 41-55.
31. Qu Y, Lipkovich I. Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach. Stat Med. 2009;28:1402-14. [PMID: 19222021] doi:10.1002/sim.3549
32. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16:17-24. [PMID: 15613941]
33. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-97. [PMID: 17159064]
34. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390-9. [PMID: 23838105] doi:10.1161/CIRCOUTCOMES.111.000071
35. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365:2250-1. [PMID: 22085320] doi:10.1056/NEJMp1112023